HCM · HUTCHMED (China) Limited American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow HCM by emailGet an email when HCM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HCM, unsubscribe in one click. Privacy
📣 What HCM Says Is Next
in 2026 · “Phase II trial initiation in patients with alopecia areata expected in 2026, with initial data expected in 2028.”
Company press release, Jul 30, 2026 · SEC filing
fourth quarter of 2027 · “Phase IIb trial (NCT07037901) in patients with moderate-to-severe atopic dermatitis progressing, with an amended protocol and topline data anticipated in the fourth quarter of 2027.”
Company press release, Jul 30, 2026 · SEC filing
second half of 2026 · “Rolling data planned to be submitted in the second half of 2026.”
Company press release, Mar 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full HCM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HCM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.